VCYT Stock Analysis: Buy, Sell, or Hold?
VCYT - Veracyte, Inc.
$42.31
0.52 (1.24%)
▲
5d:
+2.57%
30d:
-26.9%
90d:
-6.37%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When VCYT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VCYT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: VCYT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$54.69
Based on 3.1% avg growth
INTRINSIC VALUE TODAY
$33.96
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VCYT is currently trading at $42.31, which is considered oversold relative to its 30-day fair value range of $44.26 to $57.97. The stock's valuation (Forward PE: 21.7) is in line with its historical norms (24.1). Remarkably, the market is currently pricing in an annual earnings decline of 3.4% over the next few years. This pessimistic expectation contrasts with the company's recent 288.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, VCYT is in a strong uptrend. Immediate support is located at $40.09, while resistance sits at $47.75.
Market Sentiment: VCYT scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $57.82 (+36.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VCYT is in a strong uptrend. Immediate support is located at $40.09, while resistance sits at $47.75.
Market Sentiment: VCYT scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $57.82 (+36.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$44.26 -
$57.97
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 36.7% below Wall St target ($57.82)
- CAUTION: Bottoming setup, but lagging the sector by 25% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$44.26 -
$57.97
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$40.10
Resistance Level
$47.75
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.72
Wall Street Target
$57.82
(+36.7%)
Revenue Growth (YoY)
15.5%
Earnings Growth (YoY)
288.9%
Profit Margin
20.4%
Valuation Discount vs History
-3.4% cheaper
PE vs Historical
21.7 vs 24.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.4%
(market-implied from PE analysis)
1-Year Target
$40.87
(-3%)
2-Year Target
$39.48
(-7%)
3-Year Target
$38.14
(-10%)
3-Yr Target (if PE normalizes)
(PE: 22→24)
$42.32
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.7, Growth: 2.2%)
$45.15
(+7%)
Base:
(SPY PE: 20.1, Growth: 2.2%)
$41.73
(-1%)
Bear:
(PE: 17.1, Growth: 2.2%)
$35.47
(-16%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (22x PE) as earnings recover.
Trailing PE: 29.85 | Current EPS (TTM): $1.40
Bull Case
$63.97
(+51%)
Analyst growth 39.2%, PE expands to 32.8
Base Case
$58.15
(+37%)
Market implied 39.2%, PE stable at 29.9
Bear Case
$28.42
(-33%)
Severe decline -20.0%, PE contracts to 25.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.7 to 24.1
Stabilization Target:
$46.95
(+11.0%)
PE Expansion Potential:
+11.0%
Share & Embed Analysis
Last updated: August 22, 2026 3:28 PM ET
Data refreshes hourly during market hours. Next update: 4:28 PM
Data refreshes hourly during market hours. Next update: 4:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VCYT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
John Leite
SELL
5260 shares
2026-03-04
Marc Stapley
SELL
45523 shares
2026-03-04
Rebecca Chambers
SELL
18341 shares
2026-03-04
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$631 | 41 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 50 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 43 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$331 | 38 SELL |
